Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

NCT05065645 | Completed Phase 1

• 1 other identifier: APN01-01-INHAL
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

APN01 is a soluble recombinant form of the human angiotensin-converting enzyme 2 (rhACE2) that is currently under development as a therapy for corona-virus-disease 2019 (COVID-19). By effectively mimicking ACE2 within the body, APN01 is designed to block the SARS-CoV-2 from binding to the ACE2 receptor and infecting cells while at the same time downregulating the renin-aldosterone-angiotensin system (RAAS) to help prevent inflammation and organ injury - critical components involved in the cytokine storm response. ACE2 is the key entry receptor for the SARS-CoV-2. Competitive binding by exogenous angiotensin-converting enzyme 2 (ACE2) may block viral entry, thereby decreasing viral replication in ACE2 expressing organs and protecting the lungs and distal organs from injury induced by SARS-CoV-2. APN01 has been developed as an IV agent to treat acute lung injury and pulmonary arterial hypertension, and moderate to severe COVID-19 infection. Encouraged by the favorable safety profile of IV APN01, we have developed the nebulized APN01 formulation to deliver the drug directly to the respiratory tract, where the virus is mainly found, decreasing systemic exposure and increasing local pulmonary concentration. APN01 intravenously and as inhalation in preclinical studies has been well tolerated with no overall difference in clinical studies from placebo in human trials to date. This study will investigate nebulized APN01 safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity before stepping forward in proof-of-concept studies in patients with COVID-19.

Conditions

Covid19

Outcome Measures

Primary Outcomes (30)

• Adverse events

  Incidence of adverse events (AEs), serious AEs (SAEs), study withdrawals due to AEs, adverse drug reactions (ADRs), and all-cause death,

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Vital signs: Supine blood pressure assessed by systolic and diastolic blood pressure in mmHg

  Systolic and diastolic blood pressure in mmHg

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Vital signs: Resting pulse rate measured in beats per minute

  Resting pulse rate measured in beats per minute

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Vital signs: Body temperature assessed contactless via TriTemp thermometer in degree C

  Body temperature measured in degree C

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Vital signs: Respiratory rate measured in breaths/min

  Respiratory rate measured in breaths/min

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Vital signs: Peripheral oxygen saturation (SaO2) measured in %

  Peripheral oxygen saturation (SaO2) measured in %

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Clinical laboratory tests: Clinically significant changes of hematology, clinical chemistry and coagulation assessed via blood sample collection

  Clinically significant changes of hematology, clinical chemistry, coagulation and urinalysis assessed via blood sample collection

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Clinical laboratory tests: Clinically significant changes of urinalysis measurement assessed via urin collection

  Clinically significant changes of urinalysis measurement assessed via urin collection

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the general appearance

  Abnormal findings of general appearance

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the ears

  Abnormal findings of the ears

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the nose

  Abnormal findings of the nose

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the head

  Abnormal findings of the head

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the eyes

  Abnormal findings of the eyes

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the dermatologic system

  Abnormal findings of the dermatologic system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the mouth/throat/neck

  Abnormal findings of the mouth/throat/neck

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the thyroid

  Abnormal findings of the thyroid

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the lymph nodes

  Abnormal findings of the lymph nodes

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the respiratory system

  Abnormal findings of the respiratory system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the cardiovascular system

  Abnormal findings of the cardiovascular system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the gastrointestinal system

  Abnormal findings of the gastrointestinal system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the extremities

  Abnormal findings of the extremities

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the musculoskeletal system

  Abnormal findings of the musculoskeletal system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the neurologic system

  Abnormal findings of the neurologic system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Physical examination: Abnormal findings of the psychiatric system

  Abnormal findings of the psychiatric system

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Heart function: QT interval corrected for heart rate (QTc) (Bazett's correction [QTcB]) in msec assessed via Twelve lead ECG

  Twelve lead ECG: QT interval corrected for heart rate (QTc) (Bazett's correction \[QTcB\]) measured in msec

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Pulmonary function assessed via Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) measured in L by spirometry

  Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) measured in L

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Pulmonary function assessed via Peak expiratory flow (PEF) measured in L/s by spirometry

  Peak expiratory flow (PEF) measured in L/s

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Pulmonary function assessed via FEV1/FVC ratio measured in % by spirometry

  FEV1/FVC ratio measured in %

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Pulmonary function assessed via Total lung capacity (TLC) and Residual volume (RV) measured in L by body plethysmography

  Total lung capacity (TLC) and Residual volume (RV) measured in L

  SAD cohort: 2 weeks, MAD cohort: 3 weeks

• Fractional Exhaled Nitric Oxide (FeNO) levels measured in parts per billion (ppb) - in MAD cohort only

  Fractional Exhaled Nitric Oxide (FeNO) levels measured in parts per billion (ppb)

  MAD cohort: 3 weeks

Study Arms (2)

APN01

ACTIVE COMPARATOR

Angiotensin Converting Enzyme 2: 1.25 mg/ml, 2.5 mg/ml or 5 mg/ml

Drug: Angiotensin Converting Enzyme 2

NaCl

PLACEBO COMPARATOR

Sodium Chloride: 0.9% NaCl solution

Drug: Sodium chloride

Interventions

Angiotensin Converting Enzyme 2 DRUG

SAD: single dose; MAD: dosage 2x daily for 7 days

Also known as: Inhalation solution

APN01

Sodium chloride DRUG

SAD: single dose; MAD: dosage 2x daily for 7 days

Also known as: Inhalation solution

NaCl

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy males and females between 18 to 55 years of age, inclusive, at the screening visit.
• Subject voluntarily agrees to participate in this study and signs an Ethics Committee approved informed consent prior to performing any of the screening visit procedures.
• Subject is able to understand and is willing to comply with all study requirements, and willing to follow the instructions of the study staff.
• Women of childbearing potential must have a negative pregnancy test, should not be breastfeeding, and must be willing to use highly effective methods of contraception for at least 1 month before, while participating in this study and until 1 month after the end of the treatment. The following terms of contraception apply:
• Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study intervention. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment.
• Sterilization of male partner (at least 6 months prior to Screening) with post-procedural semen specimen to verify a successful procedure (the report of the male partner will not be collected since the partner is not study participant). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
• Placement of an intrauterine device or intrauterine system, or other forms of non-hormonal contraception that have comparable efficacy (failure rate \<1%).
• Women who are postmenopausal are not required to use contraception. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range (FSH \> 40 U/ml at Screening) must be used to confirm a postmenopausal state.
• Male subject must agree to stay abstinent or must use together with his female partner(s) use a form of highly effective contraceptive from the time of signing the informed consent form (ICF) until up to 3 months after receiving the study drug.
• Nonsmokers (and/or no use of other nicotine products during 1 year before screening visit).
• Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, at the screening visit.
• Healthy with no clinically significant findings, determined by medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations) at Screening.
• Forced expiratory volume in 1 second (FEV1) ≥80%.

You may not qualify if:

• Female subjects who are breastfeeding or female subjects with a positive pregnancy test at the screening visit or admission.
• Study participant has a history of an anaphylactic reaction to study drug or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
• Subject has used an investigational drug within 30 days (or 5 half-lives whichever is longer) prior to the first dose of study drug.
• Subject is on any regular (more than 4 days a week) prescription or nonprescription over the counter medication, topical medications, vitamins, dietary or herbal (occasional use of acetaminophen, paracetamol or ibuprofen allowed).
• Subject has positive urine test for drugs of abuse at the screening visit or admission.
• Regular consumption of alcohol within 6 months prior to Screening (\> 7 drinks/week for females, \> 14 drinks/week for males where 1 drink = 5 ounces \[150 ml\] of wine or 12 ounces \[360 ml\] of beer or 1.5 ounces \[45 ml\] of hard liquor), or use of illicit substances (such as marijuana) within 3 months prior to the screening visit.
• Subject has positive test for SARS-CoV-2 antigen or real-time RT-PCR, HBsAg, anti-HBc antibodies, HCV antibody, and/or HIV antibody at screening visit.
• Donation or loss of 450 ml or more of blood within 4 weeks or 250 ml of plasma within 4 weeks prior to initial dosing.
• Subject has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, mental or other medical disorder, including cirrhosis or malignancy.
• Subject has a history of a psychiatric disorder that will affect the subject's ability to participate in the study as determined by the Investigator.
• Subject has a clinically relevant abnormal ECG.
• Subject has clinically relevant abnormal laboratory values at the discretion of the Investigator.
• Subject has hypertension with a mean systolic BP \>150 mmHg or mean diastolic BP \>100 mm Hg. Screening and admission tests may be repeated once if abnormal.
• Subject has acute, clinically significant illness within 30 days prior to admission, or any other condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study.
• Subject is an employee of the clinical research team (any APEIRON Biologics AG or study center employee).

Sponsors & Collaborators

• Apeiron Biologics: lead
• Apeiron Respiratory Therapies GmbH: collaborator

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

Location

Related Publications (2)

• Bauer M, Jorda A, Al-Jalali V, Wolfl-Duchek M, Bergmann F, Nussbaumer-Proll A, Steindl A, Gugenberger R, Bischof S, Wimmer D, Idzko M, Zeitlinger M. Phase I dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of an inhaled recombinant human ACE2. ERJ Open Res. 2024 Feb 19;10(1):00567-2023. doi: 10.1183/23120541.00567-2023. eCollection 2024 Jan.

  PMID: 38375429 DERIVED

• Shoemaker RH, Panettieri RA Jr, Libutti SK, Hochster HS, Watts NR, Wingfield PT, Starkl P, Pimenov L, Gawish R, Hladik A, Knapp S, Boring D, White JM, Lawrence Q, Boone J, Marshall JD, Matthews RL, Cholewa BD, Richig JW, Chen BT, McCormick DL, Gugensberger R, Holler S, Penninger JM, Wirnsberger G. Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. PLoS One. 2022 Jul 11;17(7):e0271066. doi: 10.1371/journal.pone.0271066. eCollection 2022.

  PMID: 35816490 DERIVED

MeSH Terms

Conditions

COVID-19

Interventions

Angiotensin-Converting Enzyme 2; Sodium Chloride

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Carboxypeptidases; Exopeptidases; Peptide Hydrolases; Hydrolases; Enzymes; Enzymes and Coenzymes; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 30, 2021
• First Posted: October 4, 2021
• Study Start: October 19, 2021
• Primary Completion: May 27, 2022
• Study Completion: May 27, 2022
• Last Updated: September 23, 2022

Record last verified: 2022-02

Locations

AU (1)